Source: news.stv_.tv Health authorities in the UK have launched a formal investigation into the potential side effects of widely used Weight loss and diabetes medications following a surge in reports of pancreas-related complications Yellow Card Biobank . Nearly 400 patients have reported cases of acute pancreatitis—some of them fatal—after using GLP-1 (glucagon-like peptide-1 receptor agonists) drugs such as Mounjaro, Wegovy, Ozempic, and liraglutide. The Medicines and Healthcare products Regulatory Agency (MHRA) confirmed that over a quarter of these cases were reported in 2025 alone, with 101 incidents tied to tirzepatide (Mounjaro) and 22 to semaglutide (Ozempic and Wegovy). The agency emphasized that, although pancreatitis is listed as an “uncommon” side effect, the increasing usage of these injections has coincided with a rise in related health complaints submitted via the MHRA’s Yellow Card scheme. Acute pancreatitis, a sudden inflammation of the pancreas, can lead to severe abdominal pain, nausea, fever, and hospitalization. The health watchdog has urged both patients and healthcare professionals to report any such adverse effects to aid in the ongoing safety assessment.